How many diseases is triple negative breast cancer; the protagonism of the immune microenvironment by Saraiva, Diana P et al.
  1Saraiva DP, et al. ESMO Open 2017;2:e000208. doi:10.1136/esmoopen-2017-000208
Open Access 
AbstrAct
Triple negative breast cancer (TNBC) is a type of breast 
cancer (BC) that does not express the oestrogen and the 
progesterone receptors and the human epidermal growth 
factor receptor type 2 (HER2). Since there are no positive 
markers to reliably classify TNBC, these tumours are not 
yet treated with targeted therapies. Perhaps for this reason 
they are the most aggressive form of breast carcinomas. 
However, the clinical observation that these patients do 
not carry a uniformly dismal prognosis, coupled with data 
coming from pathology and epidemiology, suggests that 
this negative definition is not capturing a single clinical 
entity, but several. We critically evaluate this evidence in 
this paper, reviewing clinical and epidemiological data 
and new studies that aim to subclassify TNBC. Moreover, 
evidence on the role of tumour infiltrating lymphocytes 
(TILs) on TNBC progression, response to chemotherapy and 
patient outcome have been published. The heterogeneity, 
observed even at TILs level, highlights the idea that 
TNBC is much more than a single disease with a unique 
treatment. The exploration of the immune environment 
present at the tumour site could indeed help in answering 
the question ‘How many diseases is TNBC’ and will help 
to define prognosis and eventually develop new therapies, 
by stimulating the immune effector cells or by inhibiting 
immunological repressor molecules.
In this review, we focus on the prospect of the patient’s 
diverse immune signatures within the tumour as potential 
biomarkers and how they could be modulated to fight the 
disease.
IntroductIon
Breast cancer (BC) is the most common 
malignancy and the second cause of death in 
women of high income countries.1 WHO esti-
mates that by 2020 one in every eight women 
will develop BC.1 The 5-year survival for BC is 
98% for localised disease, 84% for regional 
disease, but only 23% for distant disease.2 A 
quarter of patients with early BC will relapse 
and half of the women with axillary lymph 
node involvement will relapse.2 There are 
several clinical types of BC, defined by ampli-
fication of specific markers. Steroid hormone 
receptor overexpression (oestrogen and/
or progesterone receptors: ER, PgR) define 
the most abundant type of BC. Roughly 70% 
of BC is ER-positive and/or PgR-positive3 4 
and this type of BC is amenable to hormonal 
therapy. Human epidermal growth factor 
receptor type 2 (HER2) amplification, defines 
a second type, with an incidence of roughly 
20%5 and it is responsive to anti-HER2 
directed therapy, namely trastuzumab and, 
more recently, lapatinib, pertuzumab and 
TDM1.6 HER2+ BC can be either ER+ or ER−, 
but its dominant biological driver and clinical 
feature is traceable to HER2 gene amplifi-
cation, a potent oncogene. The disease-free 
survival at 5 years for these two BC subtypes 
is over 95%.2 The ALTTO trial revealed that 
the addition of lapatinib to trastuzumab in 
patients with HER2+ BC had no benefit in 
disease-free survival.7
The remaining cases are termed triple 
negative BC (TNBC), breast carcinomas that 
neither express ER nor PgR and do not have 
overexpression of HER2. TNBC can represent 
between 10% to 20% of all BC cases8 and it is 
the subtype with the worse prognosis when 
compared with OR-positive (and/or PgR-pos-
itive) disease and HER2-positive disease.9 10 In 
fact, half a million women die in the world 
every year with BC, of which 150 000 are 
estimated to be TNBC cases,1 representing 
around 30% of the BC associated deaths. This 
may be due in part to the fact that it is the 
only clinical subtype of BC for which there 
is no approved adjuvant targeted therapy. 
In fact, in the pre anti-HER2 therapy era, 
HER2+ BC had an even more dismal survival 
than TNBC11 12 and currently HER2+ BC has 
a disease-free survival at 5 years comparable 
to hormone-positive disease. When faced 
with TNBC, clinicians are limited to the use 
of surgery, radiotherapy and chemotherapy. 
However, not all patients with TNBC respond 
to chemotherapy13–15 and this exemplifies 
what our clinical experience and emerging 
data suggest—TNBC may be more than a 
single disease.
Indeed, in the past few years there has 
been an effort to further divide TNBC cases 
in order to better understand the distinct 
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patient outcome and to develop new specific therapies 
for each TNBC subclass.16–18 In this review, we will analyse 
these new classifications and try to explore new targets 
that can be used in new therapies.
clInIcal and epIdemIologIcal heterogeneIty In tnBc
TNBC presents a considerable heterogeneity concerning 
the age of diagnosis, prognosis and response to treatment, 
to name a few. The clinical evidence for such heteroge-
neity is summarised in table 1. Normally and succinctly, 
TNBC is associated with African women, younger age, 
higher grade tumours, high mitotic index, more advanced 
stage at diagnosis, namely inflammatory BC, aggressive 
biology and poor prognosis, as shown in figure 1.19 The 
peak risk of relapse is at the third year and in this scenario 
the clinical outcome worsens. Also, survival after metas-
tasis relapse is reduced when compared with other BC 
subtypes.8
Considering the age at diagnosis, there is increasing 
evidence that TNBC may have a bimodal distribution 
with the first incidence peak in premenopausal patients 
and a second peak after 70 years of age.20–23 Prognosis of 
stage-matched premenopausal TNBC is worse than older 
age TNBC. One can speculate on the underlying biology 
that explains this difference in outcome. Premenopausal 
TNBC would be a disease with a few very powerful molec-
ular drivers, more akin to single hit neoplasms; whereas, 
geriatric TNBC would be a disease of generalised chro-
mosomal instability, a hallmark of ageing tissues and of 
geriatric cancer.24 In fact, such genomic heterogeneity 
has been observed in TNBC using deep sequencing.12 25
TNBC has an aggressive behaviour with presentation of 
de novo metastatic BC, large locally advanced breast lesion 
or metastatic disease developing shortly after adjuvant 
chemotherapy.26–28 TNBC frequently metastasises to the 
viscera, liver, lung or brain.29–32 However, this is not always 
the case as it may also have an oligometastatic pheno-
type closer to ER+ BC, with only lymph node and bone 
disease.33 TNBC is also heterogeneous in terms of time of 
recurrence (figure 2). Unlike ER+ BC, whose recurrence 
curve is linear, TNBC has a higher rate of recurrence in 
the first 5 years and a lower rate of recurrence afterwards; 
nevertheless, there appears to be two distinct recurrence 
peaks.23 34 The pattern of late recurrence is generally asso-
ciated with less aggressive disease, frequently with bone 
metastases.9 33 The apparent different paths of tumour 
progression in TNBC might be driven by confounding 
factors. These differences may be just a proxy for age of 
Table 1 Clinical, epidemiological and therapeutic 
heterogeneity of triple negative breast cancer (TNBC)
Characteristics Worse outcome Better outcome
Age of presentation Young Old
Stage at presentation Advanced Early
Growth rate Fast Slow





Body mass index High Low
Ethnicity African Caucasian
Figure 1 An inflammatory triple negative breast cancer 
of an African woman before (A) and after (B) treatment. 
Patients that descend from African ethnicity have a 
higher probability of developing more aggressive forms 
of breast cancer with lower curability rates. In fact, this 
patient, although the breast mass decreased (B), did not 
respond to the treatment and developed very aggressive 
meningeal carcinomatosis (C) 6 months after diagnosis 
while still finishing neoadjuvant chemotherapy with an 
opening pressure in the lumber tap of 40 mm Hg (normal 
15–20 mm Hg) and died within 2 weeks of this diagnosis 
despite intrathecal treatment.
Figure 2 Heterogeneity in the natural history of triple 
negative breast cancer. Metastasis develop preferentially 
in the viscera in patients that relapse more rapidly, leading 
to a bad prognosis. On the other hand, patients with later 
relapse present TNBC with a tendency to develop bone 
metastasis, leading to a better prognosis.
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incidence;35 additionally, the group of patients that have 
late recurrence and good prognosis, may represent the 
10% of tumours that are false negatives for ER.36
african patients
The association between African women or women with 
African ancestry and increased susceptibility to more 
aggressive BC goes back to the 1990s, before BC subtypes 
were part of our thought process. At this time, it was 
known that BC in African women was more frequently 
ER-negative, affected younger women and, when stage 
and age matched, had worse prognosis.37–39 Indeed, 
African women have more frequently premenopausal 
aggressive TNBC21 40–42 and their risk of developing TNBC 
is three times higher, independent of other risk factors 
for BC.43 Moreover, Caucasian and Asian women tend to 
have TNBC with a later age of onset and less aggressive 
clinical course,44–46 but still with bad prognosis.47 African 
women are less responsive to neoadjuvant chemotherapy 
(NACT) and have worse prognosis when diagnosed with 
locally advanced TNBC.48
Regarding incidence, TNBC has been defined as a 
rare disease in northern Europe and in some states 
of the USA,49 accounting for less than 15% of BC cases.50 
Whereas in some US states, where more than 20% of the 
population is African, the frequency of TNBC is substan-
tially higher. African premenopausal women were twice 
as likely to have TNBC than Caucasian women in North 
Carolina (39% vs 14%)40 and Atlanta cohorts (47% vs 
22%).21 Additionally, an epidemiological study from 
Nigeria reported that 59% of BC cases in their country 
were TNBC.41
A possible explanatory factor for these ethnicity-based 
differences may be the breast density, which is higher 
in African women, and the rigidity of the extracellular 
matrix can be a factor that drives the malignancy.51 52 
Also, cancer in dense breasts is harder to diagnose by 
mammography,51 53 raising the possibility that the worse 
prognosis in these cases might be due to a delay in 
diagnosis. However, stage matching in epidemiological 
studies eliminates this hypothesis.54 55 Additionally, denser 
mammary glands may have distinct growth factor profiles 
that predispose women to more aggressive cancer with 
oestrogen independence. This difference may also be 
caused by the fact that African women can have a distinct 
subtype of TNBC that could be more aggressive and more 
resistant to chemotherapy when compared with women 
from other ethnicities. This hypothesis will be further 
explored later in this review.
An analysis of outcome of 25 000 patients with cancer 
enrolled in the Southwest Oncology Group phase III clin-
ical trial54 showed that ethnicity does not affect outcome 
of carcinoma of the lung, colon, lymphoma, leukaemia 
or multiple myeloma; but that it affects sex hormone 
responsive carcinomas of the breast, ovary and prostate. 
Biologically, there are data suggesting TNBC in Africans 
has more signalling through growth factor pathways such 
as insulin growth factor receptor type 1 (IGF1) and the 
vascular endothelial growth factor-activated genes,56 
although IGF1 signalling is increased in obese individ-
uals, which was not controlled in this study, and African 
women have higher body mass index than Caucasians. In 
fact, the link between obesity and TNBC was shown in the 
Carolina Breast Study.40 Moreover, the stem cell renewal 
pathway Wnt β-catenin is active in TNBC57 and specifi-
cally more active in tumours of African patients.58 The 
stem cell marker ALDH1 was studied with tissue microar-
rays in a cohort of 192 TNBCs from Ugandan patients 
and was found to be present in 48% of the tumours and 
correlated with high histological and nuclear grades.59
response to chemotherapy
One of the most striking causes of heterogeneity of TNBC 
is the different sensitivity to chemotherapy, where patients 
are either chemoresponsive or chemoresistant.60 On one 
hand, TNBCs are among the most chemoresponsive BCs: 
data from neoadjuvant studies show that the fraction of 
tumours experiencing pathological complete response 
(pCR) is mostly comprised of TNBC.60–65 On the other 
hand, TNBCs are frequently chemoresistant tumours as 
documented by the short survival of patients with meta-
static disease in published series.66 67 One could argue 
that the apparent chemoresponsiveness found in neoad-
juvant studies evolves into a chemoresistant phenotype. 
Nevertheless, this does not seem to be the case since, 
in large neoadjuvant trials with long follow-up, those 
women that obtain a pCR consistently maintain survival 
advantage over the years.68 This suggests that chemosen-
sitivity is a hard-wired feature of a particular tumour.69 
Chemoresistance is linked to abundance of stem-like 
cells that are pluripotent and quiescent and are therefore 
able to undergo epithelial to mesenchymal transition 
(EMT) and are resistant to therapy that targets dividing 
cells. In gene expression studies, these TNBCs enriched 
in cells that have properties similar to stem cells are clas-
sified as claudin low tumours.70
Due to this heterogeneity in response rates to stan-
dard chemotherapy, several other therapeutic strategies 
are being analysed (table 2). These strategies encompass 
poly (ADP-ribose) polymerase inhibitors (PARPi) and 
platinum agents (see next section); anti-VEGF drugs,71 72 
namely bevacizumab; capecitabine, which is a prodrug 
that is converted to fluorouracil;72 or ixabepilone that 
stabilises microtubules.73 74 Although these approaches are 
still being tested in clinical trials, the most promising one 
is the use of olaparib (a PARPi) in HER2-negative meta-
static disease with germline BRCA mutation (gBRCAm).75 
The other clinical trials are still ongoing or haven’t shown 
significant differences between patient arms.
Moreover, there is increasing evidence that anticancer 
immune responses may contribute to the control of 
cancer after conventional chemotherapy.76 Therefore, 
as we later explore, the fact that TNBC tumours exhibit 
a high heterogeneous immune microenvironment, may 
also be associated with the different chemoresistance/
chemosensitivity profiles among TNBC.
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Due to the different levels of heterogeneity in TNBC 
here described, it was essential to come up with a subclas-
sification of TNBC in order to develop new targeted ther-
apies, especially in the cases where chemotherapy is not 
effective.
the trIple negatIve suBclassIfIcatIon
In general, BC can be classified into multiple subtypes 
according to different criteria. TNBC can be further 
subtyped using histological, developmental and molec-
ular criteria.
Histologically, the majority of TNBC is grade 3 or poorly 
differentiated (figure 3).77 78 The few remaining cases 
are rare histological types like adenoid-cystic, medullary, 
apocrine, metaplastic or inflammatory BCs.79–82
There have been attempts to establish a relationship 
between normal mammary gland development and 
occurrence of BC, that is, to map different types of BCs 
into different stages of the mammary gland develop-
ment,83 as has been done for acute myeloid leukaemia.84 
Some TNBCs would correspond to a more primitive 
subtype of tumour, closer to the most undifferentiated BC 
progenitor cell (stem cell). This reasoning is supported 
by the observation that the putative BC stem cells in 
in vitro models are ER-negative and that, as they subse-
quently differentiate into mammary gland luminal cells, 
acquire ER.85 86 Thus, some TNBCs might be more similar 
to the BC stem cell phenotype, showing a capacity to 
undergo EMT and reprogramming of embryonic genes, 
whereas others would not.87 88 This hypothesis is now 
Table 2 Ongoing clinical trials with PARP inhibitors (PARPi), anti-VEGF, ixabepilone and capecitabine drugs, divided by 
metastatic, neoadjuvant or adjuvant setting, regimen and efficacy













II Metastatic (with 
gBRCAm)
Talazoparib (PARPi) in patients 
previously exposed to 
platinum or multiple cytotoxic 
regimens
Talazoparib is well tolerated 





III Metastatic Talazoparib (PARPi) in patients 
who have received prior 
chemotherapy for metastasis





II/III Neoadjuvant (TNBC 
or gBRCAm)
Adding olaparib (PARPi) 
to neoadjuvant platinum 
or multiple prior cytotoxic 
regimens
Ongoing, no results 
published
145
NCT02282345 II Neoadjuvant (invasive 
BC and deleterious 
BRCAm)
Talazoparib (PARPi) Ongoing, no results 
published
146
NCT00148694 II Neoadjuvant (TNBC) Cisplatin pCR=22% 147
NCT02199418 II Neoadjuvant Paclitaxel and cisplatin pCR=64.7% (in TNBC) 100
NCT00483223 II Metastatic (TNBC) Cisplatin or carboplatin ORR=25.6% 148
NA NA Metastatic Carboplatin and paclitaxel ORR=56.6% (in TNBC) 149
BEATRICE
NCT00528567
III Adjuvant (TNBC) Bevacizumab (anti-VEGF) No differences in overall 
survival; prior patient 
selection must be 
performed.
71
NCT01069796 II Metastatic (TNBC) Bevacizumab, paclitaxel, 
capecitabine





III Adjuvant (TNBC) Ixempra (ixabepilone) versus 
Taxol
No differences in disease-
free survival and overall 
survival with Ixempra
73
NCT00633464 II Metastatic (TNBC) Ixabepilone and 
ixabepilone + cetuximab 
(EGFR inhibitor)




BC, breast cancer; gBRCAm, germline BRCA mutation; NA, non applicable; ORR, objective response rate; PARPi, poly (ADP-ribose) 
polymerase inhibitor; pCR, pathological complete response; TNBC, triple negative breast cancer; EGFR, epidermal growth factor receptor.
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being analysed in the new molecular characterisation of 
TNBC studies16–18 and would be concordant with the data 
on chemoresistance of some TNBCs. The link between 
breast development and tumorigenesis is conceptually 
appealing, however more studies need to be performed 
on this topic.44 89
Although histological and developmental classifications 
are informative, most of the progress in TNBC subclassifi-
cation has been performed by molecular studies.
The first molecular observation was based on BRCA1 
mutations; however, only for a small number of TNBC 
cases, since at the most only 20% of patients with TNBC 
have this mutation.90 91 A proportion of the women 
with TNBC carry BRCA1 germline mutations, but this 
proportion varies with age of diagnosis and family history 
(figure 3).92 The role of BRCA1 null TNBC arising in 
non-BRCA1 germline mutation carriers is not yet clear. 
Furthermore, 80% of the BCs arising in BRCA1 germ-
line mutation carriers are TNBC but with good prog-
nosis.93 Deep sequencing of BC genomes revealed that 
the BRCA1 null TNBC shows less genomic instability than 
the non-BRCA null TNBC.12 25 BRCA1 status may thus be 
suggesting two distinct TNBCs. BRCA1-deficient TNBC, 
germline or somatic, is likely a different biological entity, 
deficient in DNA repair, and, therefore, responsive to 
therapy with PARPi and platinum salts.94 This assump-
tion is being tested in current randomised clinical trials 
in TNBC. However, clinical trials with PARPi have shown 
distinct outcomes, as the results are either quite prom-
ising95 96 or have failed to achieve any response in these 
patients.97 98 Platinum salts are also being used in trials 
with promising results, as depicted in this meta-analysis.99 
New data on neoadjuvant platinum trials in TNBC have 
shown a high pCR100 (table 2). More recently, olaparib 
and talazoparib, both PARPi, are being used in several 
clinical trials (table 2) to treat patients with gBRCAm. The 
OlympiAD—a phase III clinical trial that analyses the use 
of olaparib versus standard chemotherapy in HER2-neg-
ative metastatic BC with gBRCAm, found that progres-
sion-free survival was improved in the olaparib arm, the 
time to second progression was longer and there were 
less adverse events, increasing the health-related quality 
of life in these patients.75
Besides BRCA1 mutations, other TNBC categories have 
been described. For instance, Lehmann et al molecularly 
divided TNBC in six different subtypes according to their 
unique gene expression profiles.17 These subtypes were 
classified as basal-like (BL1 and BL2), immunomodula-
tory (IM), mesenchymal (M), mesenchymal stem-like 
(MSL) and luminal androgen receptor (LAR). The first 
two subclasses had a basal-like phenotype with higher 
expression of cell cycle and DNA damage response genes 
and BL2 also had increased growth factor signalling. 
The IM subtype had elevated immune cell signalling and 
cytokine signalling. Mesenchymal and MSL subtypes had 
augmented gene expression for EMT events, cell motility 
and differentiation. In addition, the MSL class had lower 
levels of proliferation genes and increased gene expres-
sion related with stem cells. Finally, the LAR subclass had 
increased levels of androgen receptor (AR) and luminal 
gene expression patterns. Within these subclasses, the 
response to therapeutic inputs was distinct, as well as the 
relapse-free survival and distant metastasis-free survival.
More recently, a new classification was described 
by Burstein et al.18 In this study, the authors assessed 
198 tumour tissues, mainly from Caucasian women, 
according to their expression profile data. They were able 
to divide TNBC in four different classes—LAR, mesen-
chymal (MES), basal-like immunosuppressed (BLIS) 
and basal-like immune-activated (BLIA). Each subtype 
had unique gene expression profiles and specific targets. 
For instance, LAR, which was similar to the subtype 
described by Lehmann, exhibited AR, ER, prolactin and 
ErbB4 signalling. MEShad increased cell cycle pathways, 
mismatch repair of DNA, DNA damage networks and 
higher IGF1. BLIS had low levels of B cells, T cells and 
natural killer (NK) cells, reduced immune-regulating 
pathways and cytokine expression; on the other hand, 
had elevated expression of SOX1. Opposite of BLIS is 
BLIA with high levels of immune cells and activation of 
STAT transcription factor mediator pathways. The BLIS 
subtype had worst prognosis with low disease-free survival, 
while BLIA had the better prognosis. Specific targets for 
each class were found: mucin 1 for LAR; platelet-derived 
growth factor (PDGF) receptor A and c-Kit for MES; 
V-Set domain containing T cell activation inhibitor 1 
(VTCN1) for BLIS and STAT signal transduction mole-
cules and cytokines for BLIA.
Interestingly, Lehmann recently published another 
work where he acknowledges the existence of only four 
subtypes, denominated TNBCtype-4.16 These subtypes 
Figure 3 Histological and molecular heterogeneity of 
triple negative breast cancer (TNBC). (A) Most TNBCs are 
infiltrating ductal carcinoma (IDC), leading to bad prognosis. 
The other types of TNBCs have better prognosis, with 
the exception of metaplastic and inflammatory. (B) There is 
a high overlap between TNBC and basal-like breast cancer, 
however, not all TNBCs are basal-like and vice versa. 
(C) Some patients with TNBC have a BRCA1 germline 
mutation, which leads to an improved patient prognosis.
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were BL1, BL2, M and LAR. In addition to the gene 
expression profiles that were executed in the first article, 
histopathological quantification and laser-capture micro-
dissection (LCM) were used. As so, the lymphocytic 
infiltration was found to be present in all six subtypes, 
in different percentages, leading to the conclusion that 
IM is not really an independent subtype but that its 
components are present in the other classes. Moreover, 
the authors found that the characteristics of the MSL 
subtype were mainly derived by the stromal component 
surrounding the tumour. Again, each of the subtypes 
had different responses to the same treatment, with 41% 
of BL1 patients and only 18% of BL2 patients achieving 
pCR.
Even though the subtypes described by Burstein or by 
Lehmann are not exactly superimposable, there seems 
to be a tendency—one class with high expression of 
AR, another with mesenchymal features and two basal-
like. In addition, lymphocytic infiltration appears to be 
present in distinct proportions across the subtypes, or at 
least prevalent in two subclasses (BLIS and BLIA). The 
important message to retrieve from these attempts to clas-
sify TNBC is that indeed tumours differ between patients 
as well as their response to the same treatment and this 
could be the basis of the heterogeneity found in the clinic 
that was described in the previous section. It is possible 
to hypothesise that young women with TNBC can have 
a subtype that is more aggressive or that doesn’t have a 
good response to a systemic untargeted treatment, such 
as BLIS for instance, when compared with menopausal 
women with TNBC. Moreover, a tumour with mesen-
chymal phenotype and with stem cell characteristics can 
be more chemoresistant than a basal-like subtype. This 
subtype could be more prevalent in African women, since 
they have a more aggressive phenotype that is more intol-
erant to treatment.
Another point in common between all classifications is 
the presence of immune cells within the tumour, either as 
a subgroup on its own—IM in Lehmann’s first classifica-
tion or BLIS and BLIA in Burstein’s study, or widespread 
through all groups as depicted in the second classifica-
tion published by Lehmann. Moreover, BLIS and BLIA 
subtypes were the ones with the worst and best prognoses, 
respectively. Thus, it seems clear that the immune system 
plays a critical role in the progression of TNBC.
the role of Immune cells In tnBc progressIon
Indeed, a few studies have described the relationship 
between tumour infiltrating lymphocytes (TILs) and 
cancer progression and patient survival, namely in mela-
noma and ovarian, breast, bladder, cervical, colon, pros-
tate, rectum and lung cancers.101–107 TILs enclose cyto-
toxic CD8+ T cells, CD4+ T helper cells (Th), CD4+/
FOXP3+ regulatory T cells (Treg), B cells and NK cells. It 
was observed that in BC and in the adjacent stroma, the 
number of TILs is higher when compared with normal 
breast tissue.108 109 Overall, the presence of TILs in BC 
seem to lead to a better prognosis and an increased 
survival rate, since chemotherapeutic drugs are more 
efficient against tumours implanted in immunocompe-
tent, with respect to immunodeficient hosts.110 111 Severe 
lymphopenia negatively affects the chemotherapeutic 
response of multiple distinct solid cancers112 and deple-
tion of CD8+ T lymphocytes in animal models also reduced 
the efficacy of chemotherapy.110 111 Hence, several reports 
have been advocating that TILs could serve as a robust 
marker for predicting pCR rate in respect to NACT.113
In a meta-analysis of studies published with predictive 
significance of TILs in pCR in cases of BC with NACT,114 
the authors observed that an increase in TILs (especially 
CD8+ and FOXP3+ cells) in biopsies from patients with 
no previous treatment led to better pCR after NACT. 
Another meta-analysis observed that an increase in TILs 
led to a reduction of 30% in the risk of recurrence, a 
decrease in 22% in the risk of distant recurrence and 34% 
less risk of death.115
Within patients with BC, the presence of TILs has been 
associated with increased pCR rates and a decreased 
risk of mortality in HER2+ and TNBC, but not in 
ER+ disease.114 116–118 We will now focus on the role of 
TILs specifically in TNBC.
A study observed that in TNBC samples, the presence of 
CD8+ cells within the tumour was associated with a reduc-
tion of 28% in mortality and the presence of these cells 
in the stroma led to a decrease of 21%.116 The presence 
of TILs correlates with pCR, and the quantity of TILs in 
the tumour microenvironment is also important, as it was 
found that the higher the number of CD8+ T cells present 
at the tumour site, the better the prognosis of patients with 
TNBC.119–121 In the past few years, a number of clinical trials 
in BC, namely in TNBC, started to implement the quanti-
fication of TILs and the possible association with survival. 
For instance, in ECOG 2197 and ECOG 1199 trials, it was 
observed that for each 10% increment in TILs (within the 
stroma), there was a 19% reduction in the risk of death.91 
Loi et al observed that each 10% increase in TILs was asso-
ciated with 27% reduction in the risk of death (BIG 02–98 
clinical trial)117 and 13% reduction in the relative risk of 
distant recurrence (FinHER trial).122 If the patients were 
treated with chemotherapy, this reduction was of 18%.122 
Thus, it is possible that the clinical efficacy of therapeutic 
regimens commonly employed to treat TNBC, namely 
chemotherapy, is largely determined by T lymphocyte-de-
pendent immune response. Indeed, in a prospective study, 
it was found that an increase in TILs in BC supports a better 
response to anthracycline/taxane-based NACT.123
However, not all studies corroborate this association 
between presence of TILs and patient outcome. In fact, 
and just as an example, Liu et al, determined that there 
was no association between CD8+ TILs infiltration and 
improved survival in TNBC that showed no expression of 
basal markers.120
Moreover, CD8+ T cells are present in immune infil-
trates within the tumour, and other T cells, such as 
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CD4+ Th and FOXP3 are also present in the tumour 
microenvironment. CD4+ Th may be correlated with 
good prognosis (higher Th1) and with poor prognosis 
(higher Th2) in BC, but not specifically in TNBC.124 Treg 
effect on prognosis is controversial, with different studies 
in TNBC affirming distinct consequences from the pres-
ence of Tregs in tumours. For instance, Mahmoud et al 
described that Treg is not an independent prognostic 
factor,119 while Lee et al claimed that improved survival 
in patients with TNBC was associated with highly infil-
trating Treg.125 It was also described that the presence of 
FOXP3 + in patients post-NACT was found to be a predic-
tive marker for a low pCR rate.114 Interestingly, it was 
described that a ratio of CD8+/FOXP3+  ≥3 in primary 
BC led to an improved overall survival, whereas if this 
ratio is <3 in metastatic BC (at first relapse), it also led 
to improved overall survival.126 In metastatic TNBC, the 
levels of CD3+, CD4+, CD8+ and FOXP3+ TILs were infe-
rior than the matched primary tumour, and metastatic 
TNBCs had fewer TILs compared with metastatic HER2+, 
ER+ or PgR+ tumours.126
Besides CD4+, CD8+ and FOXP3+ TILs, other cells from 
the immune system can have a pivotal role in TNBC progres-
sion, as tumour associated macrophages (TAMs), dendritic 
cells (DCs), tumour associated neutrophils (TANs), myeloid 
derived suppressor cells (MDSCs) and NK cells.127–129 
Nevertheless, few studies have been developed that focus 
on these cells from the immune system and their possible 
association with patient outcome.
The information input that is used nowadays in the 
clinic for patients with TNBC is not sufficient to distin-
guish between patients who have a high chance to have a 
pCR when treated with conventional NACT from patients 
who cannot achieve a pCR and could benefit more from 
alternative immunotherapies. The information provided 
by the clinical measure of TILs pretreatment could be an 
answer to help in decision making regarding the treat-
ment of different patients with TNBC. Stratification 
of patients based on the presence of TILs, and more 
specifically the subtype and the phenotype of TILs, will 
be paramount in the future to provide quality treatment 
to non-responders to conventional systemic therapy. 
Indeed, immunotherapy is not yet a reality for patients 
with TNBC, since the clinical trials implemented so far 
had a low response rate,130 probably due to poor charac-
terisation of the immune environment and subsequent 
suboptimal patient stratification.
potentIal new targeted therapIes for tnBc 
consIderIng Its Immune mIcroenvIronment
The success of NACT may be interrupted by distinct strat-
egies employed by tumour cells to induce anergy/exhaus-
tion of effector CD8+ T cells and Th1 cells, namely by defec-
tive antigen presentation, by engaging the T cell receptor 
in the absence of co-stimulation, by shifting the balance 
from Th1 to Th2 (immune deviation), by expressing 
inhibitory molecules like PD-L1 which bind the inhibitory 
receptor PD-1 in effector T lymphocytes, inducing nega-
tive regulatory pathways that limit the activity of these 
cells.131 132 Other inhibitory immune checkpoints, such 
as CTLA-4, Tim-3 or LAG-3 and the secretion of extrinsic 
immunosuppressing molecules such as interleukin 
(IL) 10, TGF-β, indoleamine 2,3-dioxygenase (IDO) or 
arginase could also directly or indirectly (by recruiting 
MDSCs and Tregs) negatively impact effector T cells’ 
actions.131 132 CTLA-4 is also expressed at the surface of 
T cells and can suppress their function by binding to B7 
ligands. Tumour cells can express these ligands on their 
surface to escape the immune system.133 Tim-3 is a cell 
surface receptor present in CD4+ and CD8+ T cells with an 
inhibitory function.134 Tests performed in mouse models 
of BC found a high number of CD8+ T cells with Tim-3 
expression infiltrating the tumour120 and the blockage of 
Tim3 led to an increase in antitumour immunity.120 121 
IDO is an immunosuppressive enzyme present in DCs, 
macrophages and tumour cells.122 By using an IDO inhib-
itor, it would be possible to increase the level of matu-
ration of these cells that are able to present tumour-as-
sociated antigens to effector cells. Another interesting 
approach to boost the antitumour response would be by 
the use of Ox40 agonists, since Ox40 is a co-stimulatory 
receptor present in T cells.123 124 Moreover, several other 
molecules with immune checkpoint properties are now 
being discovered and studied in different malignancies, 
such as CD39, CD73, TIGIT, CD96 and CD47.135–137
Blocking these immunosuppressing mechanisms to 
augment T lymphocyte function seems a promising 
approach to treat cancer.131 132 138 Indeed, these proteins 
are beginning to be used in anticancer therapeutics, as 
FDA approved one antibody against CTLA-4 (ipilimumab), 
two against PD-1 (pembrolizumab and nivolumab) for 
the treatment of melanoma and also two against PD-L1—
atezolizumab and avelumab, for bladder cancer and squa-
mous non-small cell lung cancer treatment, respectively.139
As TNBC appears to have high infiltration of cells from 
the immune system, it would be interesting to analyse the 
level of these immune checkpoints on TNBC samples. In 
fact, the PD-1 inhibitor pembrolizumab is being tested on 
patients with TNBC in a phase II clinical trial with some 
promising results.125 Pembrolizumab is also being anal-
ysed as an addition to standard NACT in two different 
trials—KEYNOTE 173 and I-SPY 2. In the first clinical trial, 
TNBC pCR rates are 90% (NACT+pembrolizumab) and 
100% with carboplatin addition.140 In the I-SPY trial, pCR 
rates were 2%.141 In a metastatic setting (KEYNOTE 86), 
it was possible to observe that patients that had increased 
response to pembrolizumab had lower LDH and no liver 
nor visceral metastasis.142 Thus, it seems that immuno-
therapy in a metastatic setting has a higher response in 
less aggressive cases.
A growing body of evidence shows that the type of immune 
response influences the efficiency of several chemothera-
peutic drugs116 and therefore selective immunotherapeutic 
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interventions alone or in synergism with more conventional 
anticancer agents are now more appealing.
The blockade antibodies against T cell checkpoint 
molecules including CTLA-4 and the PD-1/PD-L1 axis 
in monotherapy or combination therapies have begun 
to revolutionise the current standard cancer treatment 
in various cancer types, such as melanoma, lung cancer, 
bladder cancer and Hodgkin’s lymphoma.132 This treat-
ment is still not used in TNBC, because the genetic 
instability of tumour cells, which is frequent in this type 
of disease, make it a bad candidate for the success of 
targeted immunotherapies. However, the implementa-
tion of patient stratification by evaluating TILs and their 
phenotype in the clinic may improve the use of immuno-
therapies in this subtype of BC. Indeed, with the evalua-
tion of the tumour-immune microenvironment it would 
be possible to distinguish patients that benefit from stan-
dard chemotherapy alone from those who would benefit 
more from these new monoclonal antibodies alone or in 
combination with chemotherapeutic agents.
Besides these immune checkpoint inhibitors, other 
approaches could be interesting for the development of 
new therapies. For instance, the BLIS subtype described 
by Burstein has an immunosuppressed environment 
that is translated to the gene expression profile of these 
tumours. There are some genes important for the regu-
lation and activation of the immune system effectors 
that are downregulated in BLIS samples compared with 
controls. Since this subtype is the one with the worst 
prognosis it is of foremost importance to discover new 
ways to treat these patients. The external upregulation of 
these genes may be one of the methods to overcome the 
immunosuppression in this subtype. Interestingly, some 
of these genes are upregulated in BLIA, which demon-
strates their importance in the activation of the immune 
environment. Among these genes are CXCL9, CXCL13, 
GZMB, GZMA, CD2, CD69, PTPRC and TLR8.
conclusIons
TNBC is still a problem in the clinic, due to the lack of 
targeted therapies. Additionally, patients with TNBC have 
a high level of divergence between them, concerning age 
of diagnosis, the prognosis and the response to treatment. 
Thus, we are convinced from our clinical observations, 
laboratory data and from the literature that TNBC is not 
a single disease and that the subclassification of this clin-
ical entity with clinical phenotype correlates is an unmet 
clinical need in BC.
In order to understand this heterogeneity and to 
develop new therapies, researchers have tried to uncover 
the basis of this diversity, using histological and molec-
ular tools. Although it seems that no consensus has yet 
been made, some advances point to the same direction 
and patient segregation can be achieved: TNBC arising 
in patients with the BRCA1 germline mutation, TNBC 
associated with an immune phenotype with lymphocytic 
infiltration or TNBC arising in African-descent patients 
that is more chemoresistant.
So, to improve patient welfare, it is likely that several 
therapeutic strategies will be implemented according 
to the subtype of TNBC. These therapies can go from 
PARPi or platinum agents, for BRCA1 mutation carriers, 
to immune checkpoint inhibitors, that can modulate the 
tumour immune microenvironment to stimulate immune 
responses and control tumour progression.
Nevertheless, the findings in this area are still prelimi-
nary and more studies need to be performed to ascertain 
the true effect of these treatments in TNBC treatment.
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